{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'treatment course and continuing for a minimum of 1 month', 'following treatment with alemtuzumab.', 'Route(s) of administration:', 'Methylprednisolone: IV', 'Acyclovir: Oral', 'Prednisone/Prednisolone: Oral', 'Long-acting, nonsedating, nonselective antihistamine: Oral and/or IV', 'H2-receptor antagonist: Oral', 'Dose regimen:', 'See above', 'ENDPOINTS', 'Primary endpoint:', 'The number of new or enlarging T2 lesions on brain MRI,', 'during continuation of prior DMT (Period 1) compared to an', 'equal period after the first course of alemtuzumab treatment', '(Period 2).', 'Secondary endpoints:', 'Efficacy:', 'The number of patients with new or enlarging T2 lesions', 'during continuation of prior DMT (Period 1) compared to an', 'equal period after the first course of alemtuzumab treatment', '(Period 2).', 'EDSS (descriptive statistics, eg, percentages of', 'stable/improved/worsened since the end of Period 1).', 'Annualized relapse rate (ARR) at Year 2.', 'Cognition test scores: Brief Visuospatial Memory', 'Test - Revised (BVMT-R) and Symbol Digit Modality Test', '(SDMT); administered at least every 6 months over 2 years.', 'QoL:', 'Established generic paediatric QoL measures administered', 'every 6 months over 2 years.', 'Pharmacokinetics/Pharmacodynamics:', 'PK serum concentration and PK parameters (Cmax, Tmax, AUC,', 'AUClast, T1122) calculated where possible.', 'PD assessment including lymphocyte subsets.', 'Safety endpoints:', 'Safety and tolerability of alemtuzumab for up to 4 years after', 'last dose of alemtuzumab.', 'Assessment of development of antialemtuzumab antibodies', 'at baseline, and post dose Months 1, 3, 12 (prenext dose),', '13, 15, and 24/at EOTP; and annually in the Safety', 'Monitoring Phase.', 'Exploratory endpoint', 'T1 weighted lesions and brain volume will be assessed on', 'MRI as an exploratory endpoint throughout the study period.', 'Property of the Sanofi Group - strictly confidential', 'Page 8', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'ASSESSMENT SCHEDULE', 'Efficacy', 'EDSS: Screening, D-14 to D-7, M4, M8, M12, M15, M18,', 'M21, M24/at end of treatment phase (EOTP); every 6 months', 'in Safety Monitoring Phase, and at every relapse visit.', 'Brain MRI: Screening, D-14 to D-7, M4, M8, M12, M24/at', 'EOTP; annually in Safety Monitoring Phase.', 'SDMT: Screening, D-14 to D-7, M4, M8, M12, M18, M24/at', 'EOTP; annually in Safety Monitoring Phase.', 'BVMT-R: Screening, D-7, M4, M8, M12, M18, M24/at EOTP;', 'annually in Safety Monitoring Phase.', 'QoL Questionnaires: Screening, D-7, M4, M8, M12, M18,', 'M24/at EOTP; annually in Safety Monitoring Phase.', 'Safety', 'Adverse event (AE) reporting at each visit.', 'Physical examination and vital signs: Screening, D-14 to D-7,', 'MO/D1, M4, M8, M12, M15, M18, M21, M24/at EOTP; every', '6 months safety monitoring phase, and at every relapse visit,', 'if applicable.', 'Additionally, vital signs will be collected hourly during', 'alemtuzumab infusion and post infusion observation for', '2 hours.', 'Clinical chemistry laboratories: Screening, D-14 to D-7, M4,', 'M8, M12, M15, M18, M21, M24/at EOTP; quarterly in safety', 'monitoring phase. In addition, serum creatinine and alanine', 'aminotransferase will be assessed at M0/D1, monthly in', 'alemtuzumab treatment phase (Year 1 and 2); monthly in the', 'safety monitoring phase (inclusive of chemistry panel).', 'Hematology: Screening, D-14 to D-7, M0/D1, and monthly in', 'alemtuzumab treatment phase (Year 1 and 2); EOTP and', 'monthly in safety monitoring phase.', 'Urinalysis: Screening, D-14 to D-7, monthly in alemtuzumab', 'treatment phase (Year 1 and 2); EOTP and monthly in safety', 'monitoring phase.', 'Thyroid function tests: Screening, D-14 to D-7, quarterly in', 'both Alemtuzumab Treatment Phase (Year 1 and 2); EOTP,', 'and in safety monitoring phase.', 'Tanner staging: Screening, M12, M24/at EOTP; annually in', 'safety monitoring phase.', 'Pregnancy testing (females only): Screening (blood test), D-', '14 to D-7 and M12 (urine test).', 'Assessment of ADA: M0/D1 (baseline), M1, M3, M12 (prior to', 'second course being administered), M13, M15, and M24/at', 'EOTP; annually in safety monitoring phase.', 'Pharmacodynamics', 'Lymphocyte phenotyping: Screening, D-14 to D-7, M1, M4,', 'M8, M12, M13, M15, M18, M21, M24/at EOTP; annually in', 'Safety Monitoring Phase.', 'Pharmacokinetics', 'Property of the Sanofi Group - strictly confidential', 'Page 9', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}